Figure 9.

Acute tetrad effects in male C57BL/6 mice. Male mice aged 6–12 weeks were treated with 0.1–10 mg/kg i.p. of phytocannabinoids and assessed for catalepsy (a–c, 5 min post-injection), body temperature (d–f, 10 min post-injection), nociception in the tail flick assay (g–i, 15 min post-injection), and both locomotion (j–l) and time in the centre quadrant (m–o) in the OFT 1 h post-injection. THC-like compounds are shown in panels a, d, g, j, and m. CBD-like compounds are shown in panels b, e, h, k, and n. CBG, and CBC are shown in panels c, f, i, l, and o. (a–c) Catalepsy data are expressed as the % maximum possible effect (MPE, i.e. 60 s). (d–f) Body temperature data are expressed as change (∆) from baseline (°C). (g–i) Tail flick latency data are expressed as the % maximum possible effect (MPE, i.e. 20 s). (j–l) Locomotion data are expressed as % change from baseline total distance travelled. (m–o) Time in centre quadrant data are expressed as sec during 5 min OFT trials. n = 6/treatment. All data are expressed as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001 relative to vehicle for each assay as determined via one-way ANOVA followed by Tukey’s post-hoc analyses. Asterisk colour matches the treatment group assessed.